{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:15:41Z","timestamp":1788999341436,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clgc.2017.05.024","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T15:00:27Z","timestamp":1496329227000},"page":"625-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prostate Cancer Screening in a New Era of Genetics"],"prefix":"10.1016","volume":"15","author":[{"given":"Heather H.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2017.05.024_bib1","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.05.024_bib2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.05.024_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2011.07.067","article-title":"Baseline prostate-specific antigen testing at a young age","volume":"61","author":"Loeb","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","article-title":"Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer","volume":"72","author":"Annala","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw110","article-title":"Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study","volume":"108","author":"Bratt","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2017.05.024_bib8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2007.13.3355","article-title":"Concordance of survival in family members with prostate cancer","volume":"26","author":"Hemminki","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.05.024_bib9","first-page":"946","article-title":"Initial prostate specific antigen 1.5 ng\/ml or greater in men 50 years old or younger predicts higher prostate cancer risk","volume":"183","author":"Tang","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2017.05.024_bib11","doi-asserted-by":"crossref","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2017.05.024_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrurol.2013.266","article-title":"The genetic epidemiology of prostate cancer and its clinical implications","volume":"11","author":"Eeles","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.clgc.2017.05.024_bib14","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2017.05.024_bib15","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2017.05.024_bib16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2017.05.024_bib17","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2017.05.024_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib19","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.05.024_bib20","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2017.05.024_bib21","first-page":"419","article-title":"Early detection of prostate cancer: AUA Guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.6004\/jnccn.2016.0060","article-title":"NCCN Guidelines Insights: Prostate\u00a0Cancer Early Detection, Version 2.2016","volume":"14","author":"Carroll","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2017.05.024_bib23","first-page":"96","article-title":"Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"66","author":"Smith","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2017.05.024_bib24","unstructured":"US Preventive Services Task Force (USPSTF), Screening for Prostate Cancer, Available at: http:\/\/www.screeningforprostatecancer.org, Accessed July 6, 2017."},{"key":"10.1016\/j.clgc.2017.05.024_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.05.024_bib26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jama.1993.03510070082041","article-title":"Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges","volume":"270","author":"Oesterling","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2017.05.024_bib27","first-page":"288","article-title":"Prostate Cancer Awareness Week: September 22 to 28, 1997","volume":"47","author":"Crawford","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2017.05.024_bib28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199608013350502","article-title":"Age-specific reference ranges for serum prostate-specific antigen in black men","volume":"335","author":"Morgan","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.05.024_bib29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.urology.2003.10.066","article-title":"Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population","volume":"63","author":"He","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2017.05.024_bib30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.urology.2005.03.093","article-title":"Biopsy of men with PSA level of 2.6 to 4.0\u00a0ng\/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis","volume":"66","author":"Zhu","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2017.05.024_bib31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level\u00a0< or\u00a0=4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.05.024_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/1055-9965.EPI-16-0434","article-title":"Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms","volume":"26","author":"Gulati","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clgc.2017.05.024_bib33","unstructured":"National Comprehensive Cancer Network, Genetic\/Familial High-Risk Assessment: Breast and Ovarian (Version 2.2017), Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf, Accessed July 6, 2017."},{"key":"10.1016\/j.clgc.2017.05.024_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative effectiveness of alternative prostate-specific antigen\u2013based prostate cancer screening strategies: model estimates of potential benefits and harms","volume":"158","author":"Gulati","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2017.05.024_bib35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1055-9965.EPI-14-1224","article-title":"Projecting benefits and harms of novel cancer screening biomarkers: a study of PCA3 and prostate cancer","volume":"24","author":"Birnbaum","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clgc.2017.05.024_bib36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1200\/JCO.2011.38.6060","article-title":"Online tool to guide decisions for BRCA1\/2 mutation carriers","volume":"30","author":"Kurian","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317301611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317301611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:29:23Z","timestamp":1761564563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767317301611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1558767317301611"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2017.05.024","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Screening in a New Era of Genetics","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2017.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}